Sustained Release Microparticles Inhalation for Tuberculosis Treatment: Present Issues and Prospects

Kalyani Siramsetty

doi:10.37022/jpmhs.v7i2.108

Authors

Siramsetty Kalyani Priyadarshini Institute of Pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur-522017.Andhra Pradesh, India.

DOI:

https://doi.org/10.37022/jpmhs.v7i2.108

Keywords:

Microparticles, tuberculosis, Mycobacterium tuberculosis, Antitubercular drugs

Abstract

Mycobacterium tuberculosis, the primary cause of tuberculosis in humans, is a transmissible airborne disease. One of the most significant medical advances of the 20th century was the development of medications to cure tuberculosis. It makes sense to create strategies for administering antitubercular medications orally, or through the respiratory system. The pulmonary route lowers systemic toxicity, necessitates a lower dose, and has instantaneous drug release, first pass hepatic metabolism, and side effects. Presently, the most prevalent patterns in study aim to offer the optimal dry powders in the appropriate fraction for inhalation, which can release the medication before it is eliminated through natural mechanisms.

Downloads

Download data is not yet available.

References

Aung HH, Sivakumar A, Gholami SK, Venkateswaran SP, Gorain B. An overview of the anatomy and physiology of the lung. Nanotechnology-based targeted drug delivery systems for lung cancer. 2019 Jan 1:1-20.

https://seap.taylors.edu.my/file/rems/publication/109585_5120_1.PDF

Alipour S, Montaseri H, Tafaghodi M. Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. Colloids and Surfaces B: Biointerfaces. 2010 Dec 1;81(2):521-9.

https://doi.org/10.1016/j.colsurfb.2010.07.050

Aulton ME, Taylor K, editors. Aulton's pharmaceutics: the design and manufacture of medicines. Elsevier Health Sciences; 2013.

https://search.world cat.org/title/aultons-pharmaceutics-the-design-and-manufacture-of- medicines/oclc/820450834

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. The shape and structure of proteins. InMolecular Biology of the Cell. 4th edition 2002. Garland Science.

https://WWW.ncbi.nlm.nih.gov/ books/NBK26830

Singh BG, Baburao C, Pispati V, Pathipati H, Muthy N, Prassana SR, Rathode BG. Carbon nanotubes. A novel drug delivery system. International Journal of Research in Pharmacy and Chemistry. 2012;2(2):523-32.

Chakraborty S, Rhee KY. Tuberculosis drug development: history and evolution of the mechanism-based paradigm. Cold Spring Harbor perspectives in medicine. 2015 Aug 1;5(8):a021147.

https://perspectivesinmedicine.cshlp.org/content/5/8/a021147.short

Ramalingam P, Ganapaty S, Rao CB. Quantitative Structural Activity Relationship (3D-QSAR) Studies of Some Quinoxalines Derivatives as Growth Inhibitor against Mycobacterium tuberculosis H (37) Rv. InINDIAN JOURNAL OF PHARMACEUTICAL SCIENCES 2009 Mar 1 (Vol. 71, No. 2, pp. 207-208). B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA: MEDKNOW PUBLICATIONS.

Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. Journal of Controlled Release. 2003 Jan 9;86(1):131-44.

https://europepmc.org/article/med/12490379

Ganapaty S, Ramalingam P, BabuRao CH. SAR study: impact of hydrazide hydrazones and sulfonamide side chain on in vitro antimicrobial activity of quinoxaline. Int. J. Pharmacol. Biol. 2008;2(2):13-8.

Namballa M, Adimulapu A, Jesudasan RE. QbD Assisted Optimization of Microwave-assisted Synthesis of Polyacrylamide Grafted Tragacanth: Characterization and Instrumental Analysis. Current Microwave Chemistry. 2024 Apr 1;11(1):16-29.

https://pubmed.ncbi.nlm.nih.gov/26966353

Hwisa NT, Katakam P, Chandu BR, Adiki SK. Solvent Evaporation Techniques as Promising Advancement in Microencapsulation, VRI-BMC. 1 (2013) 8.

El-Sherbiny IM, El-Baz NM, Yacoub MH. Inhaled nano-and microparticles for drug delivery. Global Cardiology Science and Practice. 2015 Mar 1;2015(1):2.

https://doi.org/10.5339/gcsp.2015.2

Ezhilarasi PN, Karthik P, Chhanwal N, Anandharamakrishnan C. Nanoencapsulation techniques for food bioactive components: a review. Food and bioprocess technology. 2013 Mar;6:628-47.

https://doi.org/10.1007/s11947-012-0944-0.

Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrobial agents and chemotherapy. 2002 Feb;46(2):267-74.

https://journals.asm.org/doi/10.1128/aac.46.2.267-274.2002

GILBERT BE. Liposomal aerosols in the management of pulmonary infections. Journal of aerosol medicine. 1996;9(1):111-22.

https://doi.org/10.1159/000445116

Gharibzahedi SM, Marti-Quijal FJ, Barba FJ, Altintas Z. Current emerging trends in antitumor activities of polysaccharides extracted by microwave-and ultrasound-assisted methods. International Journal of Biological Macromolecules. 2022 Mar 31;202:494-507.

https://www.liebertpub.com/doi/10.1089/jam.1996.9.111

Hanania NA, Braman S, Adams SG, Adewuya R, Ari A, Brooks J, Mahler DA, Ohar JA, Peters J, Sanjar S. The role of inhalation delivery devices in COPD: perspectives of patients and health care providers. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2018;5(2):111.

https://ncbi.nlm.nih.gov/pmc/articles/PMC6190525

Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis. A historical perspective. Annals of the American Thoracic Society. 2015 Dec;12(12):1749-59. https://europepmc.org/article/med/26653188

Justo OR, Moraes ÂM. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug delivery. 2003 Jan 1;10(3):201-7.https://www.tandfonline.com/doi/pdf/10.1080/713840401

Knap K, Kwiecień K, Reczyńska-Kolman K, Pamuła E. Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulation. Regenerative Biomaterials. 2023 Jan 1;10: rbac099. https://doi.org/10.1093/rb/rbac099

Kerantzas CA, Jacobs Jr WR. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. MBio. 2017 May 3;8(2):10-128. https://journals.asm.org/doi/10.1128/mbio.01586-16

Khuller GK, Kapur M, Sharma S. Liposome technology for drug delivery against mycobacterial infections. Current Pharmaceutical Design. 2004 Oct 1;10(26):3263-https://benthamscience.com/article/7007

Kumar S, Nakka S, Rajabalaya R, Kumar H, Halder T, Palanisamy M, Nanda A. Microencapsulation techniques and its practices. IJPST. 2011;6:1-23.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093624

Lutfi MF. The physiological basis and clinical significance of lung volume measurements. Multidisciplinary respiratory medicine. 2017 Dec;12:1-2. .

https://mrmjournal.biomedcentral.com/articles/10.1186/s40248-017-0084-5

Lipworth BJ. Targets for inhaled treatment. Respiratory medicine. 2000 Sep 1;94:S13-6.

https://science direct.com/science/article/pii/S0954611100801353

Levet V, Rosière R, Merlos R, Fusaro L, Berger G, Amighi K, Wauthoz N. Development of controlled-release cisplatin dry powders for inhalation against lung cancers. International journal of pharmaceutics. 2016 Dec 30;515(1-2):209-20.

https://doi.org/10.1016/j.ijpharm.2016.10.019

Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current opinion in pulmonary medicine. 2010 May 1;16(3):186-93. https://pubmed.ncbi.nlm.nih.gov/20216421/

Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharmaceutical research. 2009 Nov;26:2401-16.

https://link.springer.com/article/10.1007/s11095-009-9957-4

Miller DA, Ellenberger D, Porfirio T, Gil M. Spray-drying technology. InFormulating poorly water soluble drugs 2022 May 20 (pp. 377-452). Cham: Springer International Publishing. https://www.researchgate.net/publication/321618918_Formulating_Poorly_Water_Soluble_D rugs